Here's what we'll cover
Here's what we'll cover
If you've been hesitant to start a GLP-1 medication because of the weekly injection, you're not alone. A large segment of people who could benefit from these medications simply prefer a pill. The good news: that option is getting closer, and the competition to deliver it is intensifying.
Novo Nordisk, the maker of Ozempic and Wegovy, recently raised its financial guidance for 2025. That move signals the company's internal confidence in its pipeline, particularly around oral semaglutide for weight management. Meanwhile, Eli Lilly, maker of Mounjaro, is also developing an oral GLP-1 option, but analysts suggest Novo Nordisk may reach the finish line first.
Here's what this development actually means if you're a patient weighing your options today.
What "Oral GLP-1" Actually Means
GLP-1 stands for glucagon-like peptide-1. It's a hormone your gut naturally releases after eating. GLP-1 receptor agonists mimic that hormone to reduce appetite, slow stomach emptying, and improve blood sugar regulation.
Right now, the most widely used GLP-1 medications come as subcutaneous injections, meaning you inject them under the skin, typically once a week. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are both injectables.
An oral GLP-1 pill would work through the same basic mechanism, but delivered through a tablet you swallow daily. The challenge has always been bioavailability, which is how much of the drug your body actually absorbs when taken by mouth. Proteins and peptides like semaglutide are typically broken down in the digestive system before they can work.
Novo Nordisk solved part of this problem with Rybelsus, an oral semaglutide tablet approved for type 2 diabetes since 2019. But the doses in Rybelsus (up to 14mg) were not high enough to produce the weight loss results seen with Wegovy injections. The company's newer oral candidate targets obesity directly, with formulations designed to deliver much higher effective doses.
Where Novo Nordisk Stands Right Now
Novo Nordisk's oral obesity semaglutide program, sometimes referred to in trials as OW (once-weekly oral) or in development as oral semaglutide 25mg and 50mg doses, has shown promising data in clinical trials.
Early results from the OASIS program showed that oral semaglutide at higher doses can produce clinically meaningful weight loss, in the range of 15% or more of body weight in some trial participants. That's closer to the results seen with injectable Wegovy than anyone expected from a pill.
The company raising its financial guidance is a direct reflection of this confidence. When a pharmaceutical company upgrades its earnings forecast, it typically means management sees better revenue potential ahead, either from existing products or from a pipeline they expect to monetize soon.
For patients, this signals that an oral option from Novo Nordisk is likely not years away. Regulatory submissions may be closer than the market previously expected.
Where Eli Lilly Stands in the Race
Lilly is not sitting still. The company is developing its own oral GLP-1 candidates, including orforglipron, a small-molecule GLP-1 receptor agonist. Unlike semaglutide, orforglipron is not a peptide, which means it doesn't face the same absorption challenges. It can be taken without the strict fasting requirements that Rybelsus demands.
Lilly's phase 3 data on orforglipron for obesity is expected in 2025 and 2026. Early phase 2 results were encouraging, showing weight loss of roughly 9-15% depending on the dose and duration.
However, analysts tracking the timelines currently give Novo Nordisk an edge in reaching regulatory approval first for an obesity-specific oral GLP-1. Lilly's orforglipron may be a chemically simpler molecule, which has advantages, but Novo Nordisk has a head start in terms of clinical data volume and regulatory familiarity with semaglutide.
Why This Matters More Than You Might Think
The shift from injections to pills is not just about convenience. It could fundamentally change who has access to GLP-1 therapy.
Needle aversion is real. Studies consistently show that a meaningful percentage of patients who are candidates for injectable therapies decline or discontinue them because of needle phobia or injection anxiety. A daily pill removes that barrier entirely.
Storage and travel become simpler. Injectable GLP-1 medications require refrigeration and careful handling. A pill can sit in a medicine cabinet or travel bag without worry.
Primary care adoption could accelerate. Many primary care physicians are comfortable prescribing oral medications but feel less confident managing patients on injectables. An oral GLP-1 could push weight management deeper into everyday clinical practice.
Stigma reduction. Some patients report discomfort with the visible nature of injectable medications, whether at home or while traveling. A daily pill is more private.
None of this diminishes the effectiveness of injectables. But for a large population that has not yet started treatment, an oral option could be the deciding factor.
What the Current Oral Option Looks Like: Rybelsus
Before the higher-dose obesity pill arrives, it's worth understanding what already exists. Rybelsus (oral semaglutide, 3mg, 7mg, and 14mg) is FDA-approved for type 2 diabetes management. It is not approved for obesity or weight loss as a primary indication.
It does produce some weight loss as a side effect, typically 3-5% of body weight at the 14mg dose, which is modest compared to injectable Wegovy. Some physicians prescribe it off-label for weight management, but this is not standard practice and the weight loss results are generally less impressive.
Rybelsus also comes with specific dosing instructions. You must take it on an empty stomach, with no more than 4 ounces of plain water, and wait at least 30 minutes before eating or drinking anything else. This affects absorption significantly, and missing these instructions reduces how much drug your body actually uses.
The higher-dose oral semaglutide in development is designed to address these limitations, with absorption-enhancing formulations and potentially more flexible dosing requirements.
What This Could Mean for Pricing and Access
Here's the question most patients actually care about: will oral GLP-1 medications be more affordable than injectable ones?
The honest answer right now is: maybe, eventually, but not necessarily at launch.
New branded medications typically launch at premium prices, and oral semaglutide for obesity will likely be no exception. Novo Nordisk's injectable Wegovy launched at over $1,300 per month, and Ozempic is similarly priced without insurance.
That said, competition tends to push prices down over time. If both Novo Nordisk and Lilly have competing oral options approved within a year or two of each other, the dynamic could shift faster than it has with injectables. The oral format may also open the door wider for compounding pharmacies, although this depends heavily on regulatory decisions around shortage designations.
For patients already navigating the cost of GLP-1 medications, checking available GLP-1 coupons and comparing telehealth providers remains the most practical approach today.
Questions to Ask Your Doctor Now
You don't need to wait for an oral GLP-1 to be approved to have a useful conversation with your physician. Here are specific questions worth raising at your next appointment.
Am I a candidate for oral semaglutide (Rybelsus) today? If you have type 2 diabetes and want to avoid injections, this may already be an option worth exploring.
What is my expected weight loss with an oral versus injectable GLP-1? Your doctor can help set realistic expectations based on your individual health profile.
How will my insurance handle a new oral GLP-1 if it's approved? Formulary decisions often lag behind approvals. Planning ahead helps.
Are there reasons an oral option might not work as well for me specifically? Certain GI conditions, absorption issues, or medication interactions may make injectables a better fit regardless of preference.
Should I start an injectable now or wait for oral options? This depends on the urgency of your clinical situation. For many patients, starting treatment sooner with an injectable outweighs waiting for a pill.
No waiting list. No insurance needed.
Frequently Asked Questions
Is there an oral GLP-1 pill approved for weight loss right now?
Not yet specifically for obesity. Rybelsus (oral semaglutide) is FDA-approved for type 2 diabetes and produces modest weight loss, but a higher-dose oral version targeting obesity is still in clinical trials and not yet approved.
How does oral semaglutide compare to injectable Wegovy for weight loss?
Current data suggests that high-dose oral semaglutide may produce weight loss of 15% or more of body weight, which is closer to injectable Wegovy's results than earlier oral doses. Final phase 3 data will clarify how closely the two compare.
What is orforglipron and how is it different from semaglutide?
Orforglipron is Eli Lilly's oral GLP-1 candidate. Unlike semaglutide, it is a small molecule rather than a peptide, which means it may be absorbed more easily and taken without strict fasting requirements. It is still in phase 3 clinical trials for obesity.
Will oral GLP-1 medications be cheaper than injectables?
Probably not at launch. New branded medications typically enter the market at premium prices. However, competition between Novo Nordisk and Lilly in the oral space could accelerate price pressure compared to what we've seen with injectables.
Can I take Rybelsus for weight loss if I don't have diabetes?
Rybelsus is not FDA-approved for weight loss in people without type 2 diabetes. Some physicians prescribe it off-label, but effectiveness for weight management is limited at currently approved doses. Talk to your doctor about whether it makes sense for your situation.
Why did Novo Nordisk raise its financial guidance?
Novo Nordisk raised its 2025 financial guidance due to strong performance from existing GLP-1 products and growing confidence in its pipeline, including high-dose oral semaglutide for obesity. Raising guidance signals management's expectation of stronger revenue ahead.